Flotufolastat (18F): Difference between revisions

Latest revision as of 23:12, 5 March 2025

A radiopharmaceutical used in PET imaging of prostate cancer

Flotufolastat (18F), also known as 18F-DCFPyL, is a radiopharmaceutical used in positron emission tomography (PET) imaging to detect prostate cancer. It is a fluorine-18 labeled compound that targets the prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.

Chemical Structure[edit]

Flotufolastat (18F) is a small molecule that includes a fluorine-18 isotope, which is a positron-emitting radionuclide. The chemical structure allows it to bind specifically to PSMA, facilitating the imaging of prostate cancer cells.

Mechanism of Action[edit]

Flotufolastat (18F) works by binding to the PSMA, a transmembrane protein that is significantly upregulated in prostate cancer cells. Once injected into the body, the compound circulates and binds to PSMA-expressing cells. The fluorine-18 isotope emits positrons, which are detected by PET scanners to create detailed images of the cancerous tissues.

Clinical Use[edit]

Flotufolastat (18F) is primarily used in the detection and staging of prostate cancer. It is particularly useful in identifying metastatic or recurrent prostate cancer, providing valuable information for treatment planning. The high specificity and sensitivity of PSMA-targeted imaging make it a powerful tool in the management of prostate cancer.

Advantages[edit]

The use of Flotufolastat (18F) in PET imaging offers several advantages:

High Sensitivity and Specificity: It provides clear images of prostate cancer cells due to its specific binding to PSMA.
Non-Invasive: As a PET imaging agent, it allows for non-invasive visualization of cancerous tissues.
Early Detection: It can detect prostate cancer at an early stage, improving the chances of successful treatment.

Limitations[edit]

While Flotufolastat (18F) is a powerful imaging agent, it has some limitations:

Availability: The production of fluorine-18 requires specialized facilities, which may limit availability.
Cost: The cost of PET imaging with radiopharmaceuticals can be high.
Radiation Exposure: As with all radiopharmaceuticals, there is a degree of radiation exposure, although it is generally low.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-{{Short description|A radiopharmaceutical used in PET imaging}}
+{{Short description|A radiopharmaceutical used in PET imaging of prostate cancer}}
-{{Drugbox
-| verifiedfields = changed
-| verifiedrevid = 123456789
-| IUPAC_name = (2S)-2-[[4-[[(2S)-2-(3-fluoropropyl)cyclohexyl]carbonyl]amino]butanoyl]-N-[(1S)-1-(carboxymethyl)-2-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxamide
-| image = Flotufolastat_F-18_gallium.svg
-| image2 =
-| tradename =
-| legal_status =
-| routes_of_administration = Intravenous
-| ATC_prefix =
-| ATC_suffix =
-| CAS_number =
-| PubChem =
-| DrugBank =
-| UNII =
-| KEGG =
-| ChEMBL =
-| synonyms =
-}}
-'''Flotufolastat (18F)''' is a [[radiopharmaceutical]] used in [[positron emission tomography]] (PET) imaging. It is specifically designed for the detection of [[prostate cancer]] by targeting the [[prostate-specific membrane antigen]] (PSMA), a protein highly expressed in prostate cancer cells.
+'''Flotufolastat (18F)''', also known as '''18F-DCFPyL''', is a [[radiopharmaceutical]] used in [[positron emission tomography]] (PET) imaging to detect [[prostate cancer]]. It is a [[fluorine-18]] labeled compound that targets the [[prostate-specific membrane antigen]] (PSMA), which is overexpressed in prostate cancer cells.
+==Chemical Structure==
+[[File:Flotufolastat_F-18_gallium.svg|Chemical structure of Flotufolastat (18F)|thumb|right]]
+Flotufolastat (18F) is a small molecule that includes a [[fluorine-18]] isotope, which is a positron-emitting radionuclide. The chemical structure allows it to bind specifically to PSMA, facilitating the imaging of prostate cancer cells.
 ==Mechanism of Action==
-Flotufolastat (18F) functions by binding to PSMA, which is overexpressed on the surface of prostate cancer cells. The radiolabeled compound emits positrons, which are detected by PET scanners to produce detailed images of the cancerous tissues. This allows for precise localization and staging of prostate cancer, aiding in diagnosis and treatment planning.
+Flotufolastat (18F) works by binding to the PSMA, a transmembrane protein that is significantly upregulated in prostate cancer cells. Once injected into the body, the compound circulates and binds to PSMA-expressing cells. The fluorine-18 isotope emits positrons, which are detected by PET scanners to create detailed images of the cancerous tissues.
-==Synthesis and Radiolabeling==
-The synthesis of Flotufolastat (18F) involves the incorporation of the radioactive isotope [[fluorine-18]] into a PSMA-targeting ligand. The process requires careful handling and specialized equipment to ensure the stability and purity of the radiopharmaceutical. The radiolabeling is typically performed in a [[cyclotron]], where fluorine-18 is produced and then chemically attached to the targeting molecule.
-==Clinical Applications==
+==Clinical Use==
-Flotufolastat (18F) is primarily used in the imaging of prostate cancer. It provides high-resolution images that help in the detection of both primary and metastatic lesions. This radiopharmaceutical is particularly useful in cases where conventional imaging techniques are inconclusive. It is also used to monitor the response to therapy and to detect recurrence of the disease.
+Flotufolastat (18F) is primarily used in the detection and staging of prostate cancer. It is particularly useful in identifying metastatic or recurrent prostate cancer, providing valuable information for treatment planning. The high specificity and sensitivity of PSMA-targeted imaging make it a powerful tool in the management of prostate cancer.
-==Safety and Efficacy==
+==Advantages==
-The use of Flotufolastat (18F) in clinical settings has been shown to be both safe and effective. The radiation dose from the radiopharmaceutical is relatively low, and adverse reactions are rare. The efficacy of Flotufolastat (18F) in detecting prostate cancer lesions has been demonstrated in several clinical studies, showing superior sensitivity and specificity compared to other imaging modalities.
+The use of Flotufolastat (18F) in PET imaging offers several advantages:
+* '''High Sensitivity and Specificity''': It provides clear images of prostate cancer cells due to its specific binding to PSMA.
+* '''Non-Invasive''': As a PET imaging agent, it allows for non-invasive visualization of cancerous tissues.
+* '''Early Detection''': It can detect prostate cancer at an early stage, improving the chances of successful treatment.
-==Regulatory Status==
+==Limitations==
-Flotufolastat (18F) has been approved for use in several countries for the imaging of prostate cancer. Its approval is based on clinical trials that have demonstrated its safety and effectiveness in detecting PSMA-expressing tumors.
+While Flotufolastat (18F) is a powerful imaging agent, it has some limitations:
+* '''Availability''': The production of fluorine-18 requires specialized facilities, which may limit availability.
+* '''Cost''': The cost of PET imaging with radiopharmaceuticals can be high.
+* '''Radiation Exposure''': As with all radiopharmaceuticals, there is a degree of radiation exposure, although it is generally low.
-==Related pages==
+==Related Pages==
 * [[Prostate cancer]]
 * [[Positron emission tomography]]
@@ Line 45: / Line 33: @@
 [[Category:Radiopharmaceuticals]]
 [[Category:Prostate cancer]]
-[[Category:Fluorine-18 radiopharmaceuticals]]
+[[Category:Fluorine-18 radiotracers]]